Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CHKA | P35790 | 5/20 | 0.58 |
| ▸ | MC4R | P32245 | 1/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | NCF1 | P14598 | 1/20 | 0.53 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2412547 | 0.98 | HDAC6 (0.68) | HDAC6HRH3LMNACHKAMC4R | |
| Hydrochloric Acid SCHEMBL529195 | 0.98 | HDAC6 (0.68) | HDAC6HRH3LMNACHKAMC4R | |
| SCHEMBL16121572 | 0.90 | CHKA (0.75) | HDAC6HRH3CHKACA2NCF1 | |
| SCHEMBL28061494 | 0.88 | HDAC6 (0.71) | HDAC6HRH3LMNACHKAMC4R | |
| SCHEMBL1482327 | 0.86 | HDAC6 (0.69) | HDAC6HRH3LMNACHKAMC4R | |
| SCHEMBL12966235 | 0.86 | HDAC6 (0.69) | HDAC6HRH3LMNACHKAMC4R | |
| SCHEMBL5839834 | 0.86 | HDAC6 (0.69) | HDAC6HRH3LMNACHKAMC4R | |
| SCHEMBL65179 | 0.86 | HDAC6 (0.69) | HDAC6HRH3LMNACHKAMC4R | |
| SCHEMBL16356429 | 0.86 | HDAC6 (0.69) | HDAC6HRH3LMNACHKAMC4R | |
| SCHEMBL28818566 | 0.86 | ALDH1A1 (0.61) | HDAC6HRH3LMNAHDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111004195-B | Cabazitaxel alkalescent derivative and preparation thereof | 沈阳药科大学 | 2022-01-28 | — | — | CN | claimed |
| CN-111004195-A | Cabazitaxel alkalescent derivative and preparation thereof | 沈阳药科大学 | 2020-04-14 | — | — | CN | claimed |
| EP-2608791-A1 | A PROCESS FOR THE PREPARATION OF IMATINIB BASE | Mustafa Nevzat Ilac Sanayii A.S. (TR) | 2013-07-03 | — | — | EP | claimed |
| EP-1599462-B1 | Process of preparing imatinib | CIPLA LTD (IN) | 2013-03-27 | — | — | EP | claimed |
| WO-2012026897-A1 | A PROCESS FOR THE PREPARATION OF IMATINIB BASE | MUSTAFA NEVZAT iLAÇ SANAYU A.Ş. (TR) | 2012-03-01 | — | — | WO | claimed |
| WO-2012004801-A1 | PROCESS FOR IMATINIB MESYLATE | HETERO RESEARCH FOUNDATION (IN) | 2012-01-12 | — | — | WO | claimed |
| US-7638627-B2 | Imatinib hydrochloride; reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidineamine with 4-(4-methyl-piperazinomethyl)benzoyl chloride; improved reduction step to simplify, increase yield, improve purity | CIPLA LIMITED (IN) | 2009-12-29 | — | — | US | claimed |
| US-7507821-B2 | Process for preparing Imatinib | CHEMAGIS LTD. (IL) | 2009-03-24 | — | — | US | claimed |
| WO-2008136010-A1 | A PROCESS FOR THE PREPARATION OF HIGHLY PURE IMATINIB BASE | NATCO PHARMA LIMITED (IN) | 2008-11-13 | — | — | WO | claimed |
| US-20060173182-A1 | Process of preparing imatinib and imatinib prepared thereby | CIPLA LIMITED (IN) | 2006-08-03 | — | — | US | claimed |
| US-20060149061-A1 | Novel process for preparing Imatinib | PERRIGO API LTD. (IL) | 2006-07-06 | — | — | US | claimed |
| EP-1599462-A2 | PROCESS OF PREPARING IMATINIB | Cipla Ltd. (IN) | 2005-11-30 | — | — | EP | claimed |
| WO-2004074502-A2 | A PROCESS OF PREPARING IMATINIB | CIPLA LTD (IN) | 2004-09-02 | — | — | WO | claimed |
| US-20260070903-A1 | NOVEL PYRIDO[3,4-D]PYRIMIDIN-8-ONE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, COMPRISING SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-12 | — | — | US | disclosed |
| CN-113646307-B | Pyrido [3,4-d ] pyrimidin-8-one derivatives having protein kinase inhibitory activity and pharmaceutical compositions thereof | 韩国科学技术研究院 | 2024-07-30 | — | — | CN | disclosed |
| US-11725005-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-5521184-A | ANTITUMOR AGENTS; imatinib mesylate | CIBA-GEIGY CORPORATION (US) | 1996-05-28 | — | — | US | disclosed |
| EP-0677054-A1 | NEW ANTIPARASITIC AGENTS RELATED TO THE MILBEMYCINS AND AVERMECTINS | PFIZER INC. (US) | 1995-10-18 | — | — | EP | disclosed |
| WO-1994015944-A1 | NEW ANTIPARASITIC AGENTS RELATED TO THE MILBEMYCINS AND AVERMECTINS | PFIZER LIMITED (GB) | 1994-07-21 | — | — | WO | disclosed |
| CN-1077713-A | Pyrimidine derivatives and preparation method thereof | CIBA GEIGY AG (CH) | 1993-10-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173182-A1 | Process of preparing imatinib and imatinib prepared thereby | ABL1, ABL2, MET | HDAC6 622/4885HRH3 429/4885LMNA 3983/4885 |
| US-20060149061-A1 | Novel process for preparing Imatinib | ABL1, ABL2, PDGFRA | HDAC6 3008/4885HRH3 3511/4885LMNA 4399/4885 |
| US-20260070903-A1 | NOVEL PYRIDO[3,4-D]PYRIMIDIN-8-ONE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, COMPRISING SAME | CCNC, CKS1B, CKS2 | HDAC6 344/4885HRH3 2682/4885LMNA 1065/4885 |
| US-11725005-B2 | Compositions and methods for inhibiting kinases | MAP3K1, PACSIN2, MAP3K3 | HDAC6 733/4885HRH3 3372/4885LMNA 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.